Retour

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

News Clinical Study

NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced its final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab. The Phase 2/3 trial design and protocol are based on alignment with the U.S. Food and Drug Administration (FDA) following the Company’s Type C meeting with the FDA.

GlobeNewswire Inc. • 25/04/2024 à 13:01:00
HOOKIPA Pharma Inc. Common Stock
Adresse: 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240
Code postal: 10118
Ville: NEW YORK
Region: NY
Numéro de telephone: 0114318906360
Site internet: https://www.hookipapharma.com
Status: Active
Info de l'entreprise

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Date de référencement2019-04-18
MarchéStocks
LocaleUS
Echange principalXNAS
TypeCS
DeviseUSD
CIK0001760542
Composite figiBBG00NGMNKR4
Share Class figiBBG00NGMNKS3
Market Cap46,538,037 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employés124
Share Class Shares Outstanding9660000
Weighted Shares Outstanding9894973
Round Lot100
Date de mise à jour2024-09-19
Stats
5 derniers jours
19-09
18-09
17-09
16-09
13-09
Dernier
4.665
4.7
4.81
4.831
4.975
Variation
-0.74%
-2.29%
-0.46%
-2.89%
-3%
Ouverture
4.7
4.81
4.832
4.975
5.129
Plus haut
4.765
4.875
4.915
5.011
5.224
Plus bas
4.76
4.875
4.911
4.986
5.217
Historique
PériodeVarPlus hautPlus bas
1 semaine
-9.14%
5.224
4.76
1 mois
-10.81%
5.225
4.76
3 mois
547.22%
0.72
0.521
6 mois
534.01%
0.735
0.521
1 an
651.61%
0.6326
0.41
3 ans
-29.82%
6.64
0.41
5 ans
-41.9%
8.1572
0.41
10 ans
-67.41%
14.76
0.41
Bilans
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Assets 163,088,000 191,110,000 164,010,000 UNPUB
Current Assets 139,913,000 168,143,000 139,471,000 UNPUB
Current Liabilities 44,209,000 46,245,000 40,576,000 UNPUB
Equity 83,479,000 112,330,000 95,051,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 83,479,000 112,330,000 95,051,000 UNPUB
Liabilities 79,609,000 78,780,000 68,959,000 UNPUB
Liabilities And Equity 163,088,000 191,110,000 164,010,000 UNPUB
Noncurrent Assets 23,175,000 22,967,000 24,539,000 UNPUB
Noncurrent Liabilities 35,400,000 32,535,000 28,383,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Exchange Gains/Losses 434,000 -49,000 -118,000 UNPUB
Net Cash Flow -3,423,000 25,988,000 -27,914,000 UNPUB
Net Cash Flow, Continuing -3,857,000 26,037,000 -27,796,000 UNPUB
Net Cash Flow From Financing Activities -735,000 45,815,000 -659,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -735,000 45,815,000 -659,000 UNPUB
Net Cash Flow From Investing Activities -274,000 -445,000 -3,018,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -274,000 -445,000 -3,018,000 UNPUB
Net Cash Flow From Operating Activities -2,848,000 -19,333,000 -24,119,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -2,848,000 -19,333,000 -24,119,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Comprehensive Income/Loss -19,697,000 -18,085,000 -17,850,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -19,697,000 -18,085,000 -17,850,000 UNPUB
Other Comprehensive Income/Loss -17,000 -18,085,000 -17,850,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 22,651,000 20,695,000 25,933,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 25,833,000 24,151,000 29,537,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -19,680,000 -18,016,000 -19,066,000 UNPUB
Income/Loss From Continuing Operations Before Tax -19,475,000 -18,016,000 -19,066,000 UNPUB
Income Tax Expense/Benefit 205,000 0 0 UNPUB
Interest Expense, Operating 122,000 97,000 49,000 UNPUB
Net Income/Loss -19,680,000 -18,016,000 -19,066,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -19,680,000 -18,016,000 -19,066,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -19,680,000 -18,016,000 -19,066,000 UNPUB
Operating Expenses 25,833,000 24,151,000 29,537,000 UNPUB
Operating Income/Loss -22,657,000 -21,472,000 -22,670,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 3,176,000 2,679,000 6,867,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-14 2023-03-15
Assets 195,711,000 172,212,000 151,526,000 170,454,000
Current Assets 171,079,000 149,077,000 129,611,000 147,196,000
Current Liabilities 31,228,000 27,224,000 26,052,000 35,632,000
Equity 147,929,000 131,954,000 113,348,000 102,517,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 147,929,000 131,954,000 113,348,000 102,517,000
Liabilities 47,782,000 40,258,000 38,178,000 67,937,000
Liabilities And Equity 195,711,000 172,212,000 151,526,000 170,454,000
Noncurrent Assets 24,632,000 23,135,000 21,915,000 23,258,000
Noncurrent Liabilities 16,554,000 13,034,000 12,126,000 32,305,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-14 2023-03-15
Exchange Gains/Losses -307,000 0 -844,000 -725,000
Net Cash Flow 74,891,000 -22,944,000 -18,183,000 46,532,000
Net Cash Flow, Continuing 75,198,000 -22,944,000 -17,339,000 47,257,000
Net Cash Flow From Financing Activities 75,293,000 -2,953,000 127,000 72,271,000
Net Cash Flow From Financing Activities, Continuing 75,293,000 -2,953,000 127,000 72,271,000
Net Cash Flow From Investing Activities -1,828,000 -1,632,000 -958,000 -5,017,000
Net Cash Flow From Investing Activities, Continuing -1,828,000 -1,632,000 -958,000 -5,017,000
Net Cash Flow From Operating Activities 1,733,000 -18,359,000 -16,508,000 -19,997,000
Net Cash Flow From Operating Activities, Continuing 1,733,000 -18,359,000 -16,508,000 -19,997,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-14 2023-03-15
Comprehensive Income/Loss -17,968,000 -16,356,000 -19,647,000 -67,291,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -18,455,000 -17,357,000 -19,647,000 -67,291,000
Other Comprehensive Income/Loss 0 0 -19,647,000 -2,376,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-16 2022-08-11 2022-11-14 2023-03-15
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses 19,413,000 19,101,000 20,510,000 78,934,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 21,592,000 21,173,000 23,223,000 87,404,000
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -17,968,000 -16,356,000 -18,280,000 -64,915,000
Income/Loss From Continuing Operations Before Tax -17,968,000 -16,355,000 -18,280,000 -64,685,000
Income Tax Expense/Benefit 0 1,000 0 230,000
Interest Expense, Operating 243,000 231,000 105,000 687,000
Net Income/Loss -17,968,000 -16,356,000 -18,280,000 -64,915,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -17,968,000 -16,356,000 -18,280,000 -64,915,000
Net Income/Loss Available To Common Stockholders, Basic -17,968,000 -16,356,000 -18,280,000 -64,915,000
Operating Expenses 21,592,000 21,173,000 23,223,000 87,404,000
Operating Income/Loss -20,147,000 -18,427,000 -20,993,000 -73,155,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 1,445,000 2,746,000 2,230,000 14,249,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-12 2021-11-10 2022-03-24
Assets 169,941,000 166,156,000 142,172,000 126,045,000
Current Assets 153,340,000 143,451,000 118,577,000 102,135,000
Current Liabilities 20,116,000 33,876,000 26,638,000 27,654,000
Equity 140,055,000 125,934,000 108,086,000 89,592,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 140,055,000 125,934,000 108,086,000 89,592,000
Liabilities 29,886,000 40,222,000 34,086,000 36,453,000
Liabilities And Equity 169,941,000 166,156,000 142,172,000 126,045,000
Noncurrent Assets 16,601,000 22,705,000 23,595,000 23,910,000
Noncurrent Liabilities 9,770,000 6,346,000 7,448,000 8,799,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-12 2021-11-10 2022-03-24
Exchange Gains/Losses -406,000 79,000 -115,000 2,567,000
Net Cash Flow -15,032,000 -25,192,000 -20,256,000 -76,265,000
Net Cash Flow, Continuing -14,626,000 -25,271,000 -20,141,000 -78,832,000
Net Cash Flow From Financing Activities 101,000 85,000 -11,000 -235,000
Net Cash Flow From Financing Activities, Continuing 101,000 85,000 -11,000 -235,000
Net Cash Flow From Investing Activities -330,000 -4,624,000 -2,486,000 -12,581,000
Net Cash Flow From Investing Activities, Continuing -330,000 -4,624,000 -2,486,000 -12,581,000
Net Cash Flow From Operating Activities -14,397,000 -20,732,000 -17,644,000 -66,016,000
Net Cash Flow From Operating Activities, Continuing -14,397,000 -20,732,000 -17,644,000 -66,016,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-12 2021-11-10 2022-03-24
Comprehensive Income/Loss -17,238,000 -17,153,000 -19,569,000 -74,378,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -17,714,000 -16,860,000 -19,569,000 -74,378,000
Other Comprehensive Income/Loss 0 0 -19,569,000 1,287,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-12 2021-11-10 2022-03-24
Basic Earnings Per Share UNPUB UNPUB -1 -2
Benefits Costs and Expenses 22,539,000 22,531,000 23,913,000 94,112,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 24,473,000 24,667,000 25,040,000 100,122,000
Diluted Earnings Per Share UNPUB UNPUB -1 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -17,238,000 -17,153,000 -20,040,000 -75,665,000
Income/Loss From Continuing Operations Before Tax -17,238,000 -17,153,000 -20,039,000 -75,664,000
Income Tax Expense/Benefit 0 0 1,000 1,000
Interest Expense, Operating 219,000 218,000 234,000 898,000
Net Income/Loss -17,238,000 -17,153,000 -20,040,000 -75,665,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -17,238,000 -17,153,000 -20,040,000 -75,665,000
Net Income/Loss Available To Common Stockholders, Basic -17,238,000 -17,153,000 -20,040,000 -75,665,000
Operating Expenses 24,473,000 24,667,000 25,040,000 100,122,000
Operating Income/Loss -19,172,000 -19,289,000 -21,166,000 -81,674,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 5,301,000 5,378,000 3,874,000 18,448,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-14 2020-08-13 2020-11-12 2021-03-18
Assets 135,967,000 133,268,000 121,272,000 187,817,000
Current Assets 120,716,000 117,893,000 105,795,000 171,504,000
Current Liabilities 15,385,000 18,571,000 18,721,000 21,143,000
Equity 108,982,000 103,915,000 92,180,000 156,123,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 108,982,000 103,915,000 92,180,000 156,123,000
Liabilities 26,985,000 29,353,000 29,092,000 31,694,000
Liabilities And Equity 135,967,000 133,268,000 121,272,000 187,817,000
Noncurrent Assets 15,251,000 15,375,000 15,477,000 16,313,000
Noncurrent Liabilities 11,600,000 10,782,000 10,371,000 10,551,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-14 2020-08-13 2020-11-12 2021-03-18
Exchange Gains/Losses -87,000 142,000 189,000 -2,108,000
Net Cash Flow -8,698,000 -11,595,000 -11,023,000 29,602,000
Net Cash Flow, Continuing -8,611,000 -11,737,000 -11,212,000 31,710,000
Net Cash Flow From Financing Activities -1,284,000 -150,000 -222,000 73,420,000
Net Cash Flow From Financing Activities, Continuing -1,284,000 -150,000 -222,000 73,420,000
Net Cash Flow From Investing Activities -199,000 -1,042,000 -625,000 -2,371,000
Net Cash Flow From Investing Activities, Continuing -199,000 -1,042,000 -625,000 -2,371,000
Net Cash Flow From Operating Activities -7,128,000 -10,545,000 -10,365,000 -39,339,000
Net Cash Flow From Operating Activities, Continuing -7,128,000 -10,545,000 -10,365,000 -39,339,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-14 2020-08-13 2020-11-12 2021-03-18
Comprehensive Income/Loss -10,926,000 -7,092,000 -13,589,000 -45,496,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -11,019,000 -7,225,000 -13,898,000 -45,496,000
Other Comprehensive Income/Loss 0 0 0 -1,414,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-14 2020-08-13 2020-11-12 2021-03-18
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 0 0 0 63,666,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 16,155,000 15,911,000 20,446,000 72,869,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -10,926,000 -7,092,000 -13,589,000 -44,082,000
Income/Loss From Continuing Operations Before Tax -10,926,000 -7,092,000 -13,589,000 -44,082,000
Income Tax Expense/Benefit 0 0 0 0
Interest Expense, Operating 227,000 166,000 194,000 786,000
Net Income/Loss -10,926,000 -7,092,000 -13,589,000 -44,082,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -10,926,000 -7,092,000 -13,589,000 -44,082,000
Net Income/Loss Available To Common Stockholders, Basic -10,926,000 -7,092,000 -13,589,000 -44,082,000
Operating Expenses 16,155,000 15,911,000 20,446,000 72,869,000
Operating Income/Loss -12,459,000 -9,226,000 -16,406,000 -53,285,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 3,696,000 6,685,000 4,040,000 19,584,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2019-08-12 2019-11-12 2020-03-19
Assets UNPUB 168,095,000 152,037,000 143,745,000
Current Assets UNPUB 151,100,000 136,386,000 128,017,000
Current Liabilities UNPUB 17,383,000 12,954,000 14,755,000
Equity UNPUB 136,033,000 125,757,000 117,899,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 136,033,000 125,757,000 117,899,000
Liabilities UNPUB 32,062,000 26,280,000 25,846,000
Liabilities And Equity UNPUB 168,095,000 152,037,000 143,745,000
Noncurrent Assets UNPUB 16,995,000 15,651,000 15,728,000
Noncurrent Liabilities UNPUB 14,679,000 13,326,000 11,091,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2019-08-12 2019-11-12 2020-03-19
Exchange Gains/Losses UNPUB 284,000 -824,000 -1,026,000
Net Cash Flow UNPUB 63,932,000 -11,203,000 64,995,000
Net Cash Flow, Continuing UNPUB 63,648,000 -10,379,000 66,021,000
Net Cash Flow From Financing Activities UNPUB 76,009,000 -532,000 109,751,000
Net Cash Flow From Financing Activities, Continuing UNPUB 76,009,000 -532,000 109,751,000
Net Cash Flow From Investing Activities UNPUB -191,000 -362,000 -1,999,000
Net Cash Flow From Investing Activities, Continuing UNPUB -191,000 -362,000 -1,999,000
Net Cash Flow From Operating Activities UNPUB -11,397,000 -9,485,000 -41,731,000
Net Cash Flow From Operating Activities, Continuing UNPUB -11,397,000 -9,485,000 -41,731,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2019-08-12 2019-11-12 2020-03-19
Comprehensive Income/Loss UNPUB -12,079,000 -11,385,000 -43,970,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -11,779,000 -12,148,000 -43,970,000
Other Comprehensive Income/Loss UNPUB 0 0 -933,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2019-08-12 2019-11-12 2020-03-19
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB 0 0 54,979,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB 17,680,000 15,614,000 63,027,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -12,079,000 -11,385,000 -43,037,000
Income/Loss From Continuing Operations Before Tax UNPUB -11,979,000 -11,376,000 -43,037,000
Income Tax Expense/Benefit UNPUB 100,000 9,000 0
Interest Expense, Operating UNPUB 210,000 227,000 877,000
Net Income/Loss UNPUB -12,079,000 -11,385,000 -43,037,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -12,079,000 -11,385,000 -43,037,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -12,079,000 -11,385,000 -43,037,000
Operating Expenses UNPUB 17,680,000 15,614,000 63,027,000
Operating Income/Loss UNPUB -13,629,000 -13,576,000 -51,085,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 4,051,000 2,038,000 11,942,000
Calendrier économique
20 Septembre 2024 (heure UTC) Actuel Précédent Consensus
★
15:30
United States
SEP 17
3200.000
2400.000
★
15:30
United States
SEP 17
19700.000
12800.000
★
15:30
United States
SEP 17
-66300.000
-47800.000
★
15:30
United States
SEP 17
145300.000
140000.000
★
15:30
United States
★
15:30
United States
SEP 17
310100.000
282500.000
★
15:30
United States
★★
15:30
United States
SEP 17
19200.000
25600.000
★★
15:30
United States
★
15:30
United States
SEP 17
-89600.000
-87600.000
★
15:30
United States
SEP 17
-122900.000
-59400.000
★
15:30
United States
★
15:30
United States
SEP 17
58300.000
44700.000
★
15:30
United States
SEP 17
-134600.000
-144200.000
★
15:30
United States
SEP 17
-14200.000
-16300.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:HOOK240920C00002500 OCASPS Call American 100 2.5 BATO 2024-09-20
O:HOOK240920C00005000 OCASPS Call American 100 5 BATO 2024-09-20
O:HOOK240920C00007500 OCASPS Call American 100 7.5 BATO 2024-09-20
O:HOOK240920C00010000 OCASPS Call American 100 10 BATO 2024-09-20
O:HOOK240920C00012500 OCASPS Call American 100 12.5 BATO 2024-09-20
O:HOOK240920P00002500 OPASPS Put American 100 2.5 BATO 2024-09-20
O:HOOK240920P00005000 OPASPS Put American 100 5 BATO 2024-09-20
O:HOOK240920P00007500 OPASPS Put American 100 7.5 BATO 2024-09-20
O:HOOK240920P00010000 OPASPS Put American 100 10 BATO 2024-09-20
O:HOOK240920P00012500 OPASPS Put American 100 12.5 BATO 2024-09-20
O:HOOK240719C00000500 OCASPS Call American 100 0.5 BATO 2024-07-19
O:HOOK240719C00001000 OCASPS Call American 100 1 BATO 2024-07-19
O:HOOK240719C00001500 OCASPS Call American 100 1.5 BATO 2024-07-19
O:HOOK240719C00002000 OCASPS Call American 100 2 BATO 2024-07-19
O:HOOK240719P00000500 OPASPS Put American 100 0.5 BATO 2024-07-19
O:HOOK240719P00001000 OPASPS Put American 100 1 BATO 2024-07-19
O:HOOK240719P00001500 OPASPS Put American 100 1.5 BATO 2024-07-19
O:HOOK240719P00002000 OPASPS Put American 100 2 BATO 2024-07-19
O:HOOK240719C00002500 OCASPS Call American 100 2.5 BATO 2024-07-19
O:HOOK240719C00005000 OCASPS Call American 100 5 BATO 2024-07-19
O:HOOK240719C00007500 OCASPS Call American 100 7.5 BATO 2024-07-19
O:HOOK240719P00002500 OPASPS Put American 100 2.5 BATO 2024-07-19
O:HOOK240719P00005000 OPASPS Put American 100 5 BATO 2024-07-19
O:HOOK240719P00007500 OPASPS Put American 100 7.5 BATO 2024-07-19
O:HOOK240621C00002500 OCASPS Call American 100 2.5 BATO 2024-06-21
O:HOOK240621C00005000 OCASPS Call American 100 5 BATO 2024-06-21
O:HOOK240621C00007500 OCASPS Call American 100 7.5 BATO 2024-06-21
O:HOOK240621P00002500 OPASPS Put American 100 2.5 BATO 2024-06-21
O:HOOK240621P00005000 OPASPS Put American 100 5 BATO 2024-06-21
O:HOOK240621P00007500 OPASPS Put American 100 7.5 BATO 2024-06-21
O:HOOK240517C00000500 OCASPS Call American 100 0.5 BATO 2024-05-17
O:HOOK240517C00001000 OCASPS Call American 100 1 BATO 2024-05-17
O:HOOK240517C00001500 OCASPS Call American 100 1.5 BATO 2024-05-17
O:HOOK240517C00002000 OCASPS Call American 100 2 BATO 2024-05-17
O:HOOK240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:HOOK240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:HOOK240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:HOOK240517P00000500 OPASPS Put American 100 0.5 BATO 2024-05-17
O:HOOK240517P00001000 OPASPS Put American 100 1 BATO 2024-05-17
O:HOOK240517P00001500 OPASPS Put American 100 1.5 BATO 2024-05-17
O:HOOK240517P00002000 OPASPS Put American 100 2 BATO 2024-05-17
O:HOOK240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:HOOK240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:HOOK240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:HOOK240419C00000500 OCASPS Call American 100 0.5 BATO 2024-04-19
O:HOOK240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:HOOK240419C00001500 OCASPS Call American 100 1.5 BATO 2024-04-19
O:HOOK240419C00002000 OCASPS Call American 100 2 BATO 2024-04-19
O:HOOK240419P00000500 OPASPS Put American 100 0.5 BATO 2024-04-19
O:HOOK240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:HOOK240419P00001500 OPASPS Put American 100 1.5 BATO 2024-04-19
O:HOOK240419P00002000 OPASPS Put American 100 2 BATO 2024-04-19
O:HOOK240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:HOOK240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:HOOK240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:HOOK240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:HOOK240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:HOOK240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:HOOK240315C00000500 OCASPS Call American 100 0.5 BATO 2024-03-15
O:HOOK240315C00001000 OCASPS Call American 100 1 BATO 2024-03-15
O:HOOK240315C00001500 OCASPS Call American 100 1.5 BATO 2024-03-15
O:HOOK240315C00002000 OCASPS Call American 100 2 BATO 2024-03-15
O:HOOK240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:HOOK240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:HOOK240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:HOOK240315P00000500 OPASPS Put American 100 0.5 BATO 2024-03-15
O:HOOK240315P00001000 OPASPS Put American 100 1 BATO 2024-03-15
O:HOOK240315P00001500 OPASPS Put American 100 1.5 BATO 2024-03-15
O:HOOK240315P00002000 OPASPS Put American 100 2 BATO 2024-03-15
O:HOOK240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:HOOK240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:HOOK240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:HOOK240216C00000500 OCASPS Call American 100 0.5 BATO 2024-02-16
O:HOOK240216C00001000 OCASPS Call American 100 1 BATO 2024-02-16
O:HOOK240216C00001500 OCASPS Call American 100 1.5 BATO 2024-02-16
O:HOOK240216C00002000 OCASPS Call American 100 2 BATO 2024-02-16
O:HOOK240216P00000500 OPASPS Put American 100 0.5 BATO 2024-02-16
O:HOOK240216P00001000 OPASPS Put American 100 1 BATO 2024-02-16
O:HOOK240216P00001500 OPASPS Put American 100 1.5 BATO 2024-02-16
O:HOOK240216P00002000 OPASPS Put American 100 2 BATO 2024-02-16
O:HOOK240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:HOOK240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:HOOK240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:HOOK240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:HOOK240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:HOOK240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:HOOK240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:HOOK240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:HOOK240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:HOOK240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:HOOK240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:HOOK240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:HOOK231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:HOOK231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:HOOK231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:HOOK231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:HOOK231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:HOOK231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:HOOK231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:HOOK231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:HOOK231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:HOOK231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:HOOK231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:HOOK231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:HOOK231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:HOOK231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:HOOK231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:HOOK231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:HOOK231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:HOOK231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:HOOK230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:HOOK230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:HOOK230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:HOOK230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:HOOK230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:HOOK230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:HOOK230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
O:HOOK230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:HOOK230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:HOOK230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:HOOK230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:HOOK230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
Flux d'actualités
News squamous cell carcinoma
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight
The squamous cell carcinoma (SCC) market is experiencing robust growth due to the increasing incidence of the disease and advancements in treatment options. Over 75 companies are working on 80+ pipeline therapies to improve the SCC treatment landscape.
GlobeNewswire Inc. • Il y a 4 heures
Health Health
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead.
GlobeNewswire Inc. • Il y a 2 mois
Health Health
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer.
GlobeNewswire Inc. • Il y a 3 mois
News Clinical Study
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
NEW YORK and VIENNA, May 23, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive (HPV16+) head and neck cancers. The data were published in the Company’s abstract for the ASCO 2024 Annual Meeting and support the Company’s pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab in the first line setting.
GlobeNewswire Inc. • Il y a 4 mois
Stocks Earnings Releases and Operating Results
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and recent business highlights for the first quarter of 2024.
GlobeNewswire Inc. • Il y a 4 mois
Health Health
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers.
GlobeNewswire Inc. • Il y a 4 mois
Stocks Changes in company's own shares
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to Mark Winderlich, who was appointed Chief Development Officer of the Company effective April 1, 2024, to purchase an aggregate of 250,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. The award was granted as an inducement material to the employee’s acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $0.76 per share. The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal quarterly installments for three years thereafter, subject to the employee’s continued service with HOOKIPA on each such vesting date. The options are subject to the terms and conditions of HOOKIPA’s 2023 Inducement Plan approved by the Board of Directors in April 2023 and the terms and conditions of award agreements covering the grants.
GlobeNewswire Inc. • Il y a 5 mois
Health Health
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
NEW YORK and VIENNA, Austria, April 10, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA’s Executive Team will host an investor call summarizing the Company’s constructive regulatory interactions with the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA). HOOKIPA and the FDA have aligned on the design and protocol of the Company’s upcoming pivotal Phase 2/3 clinical trial of HB-200 in combination with pembrolizumab. The investor call will be held on April 25, 2024, at 8:00 a.m. ET. Complete details and registration information are included below.
GlobeNewswire Inc. • Il y a 5 mois
News News
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research • Il y a 6 mois
Stocks Earnings Releases and Operating Results
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
NEW YORK and VIENNA, Austria, March 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the fourth quarter and full year 2023.
GlobeNewswire Inc. • Il y a 6 mois
Voir tous
Actualités liées
Dernières actualités

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT